Q1 Results - Part 2 of 2

AstraZeneca PLC
26 April 2001

Consolidated Profit & Loss Account For Continuing Operations


                                                                 1st        1st
                                                             Quarter    Quarter

                                                                2001       2000

                                                                  $m         $m
Sales                                                         3,991      3,892
Cost of sales                                                (1,074)    (1,072)
Distribution costs                                              (30)       (63)
Research and development                                       (672)      (597)
Selling, general and administrative expenses                 (1,321)    (1,218)
Other operating income                                          161         34
Operating profit before exceptional items                     1,055        976
Exceptional items charged to operating profit                   (25)       (83)
Operating profit                                              1,030        893
Share of joint ventures' and associates' operating                -         22
profits
Profit on sale of fixed assets                                   10          -
Net interest and dividend income                                 55         19
Profit on ordinary activities before taxation                 1,095        934
Profit before taxation before exceptional items               1,110      1,017
Exceptional items charged to profit before taxation             (15)       (83)
Taxation                                                       (310)      (270)
Profit on ordinary activities after taxation                    785        664
Attributable to minorities                                       (3)        (2)
Net profit for the period                                       782        662
Earnings per Ordinary Share before exceptional items          $0.45      $0.41
Earnings per Ordinary Share                                   $0.44      $0.38
Diluted earnings per Ordinary Share                           $0.44      $0.38
Weighted average number of Ordinary Shares in issue           1,766      1,773
(millions)
Diluted average number of Ordinary Shares in issue            1,768      1,776
(millions)







Consolidated Balance Sheet
                                                             31 Mar     31 Dec

                                                               2001       2000

                                                                 $m         $m
Fixed assets                                                 7,650      7,919
Current assets                                              11,036     10,515
Total assets                                                18,686     18,434
Creditors due within one year                               (6,994)    (6,897)
Net current assets                                           4,042      3,618
Total assets less current liabilities                       11,692     11,537
Creditors due after more than one year                        (903)      (927)
Provisions for liabilities and charges                      (1,124)    (1,068)
Net assets                                                   9,665      9,542
Capital and reserves
Shareholders' funds and minority interests                   9,665      9,542





Consolidated Cash Flow Statement
                                                                    1st     1st

                                                                Quarter Quarter

                                                                   2001    2000

                                                                     $m      $m
Cash flow from operating activities
Operating profit before exceptional items                        1,055   1,077
Depreciation and amortisation                                      212     261
Decrease/(increase) in working capital and other non-cash          110    (417)
movements
Net cash inflow from operating activities before exceptional     1,377     921
items
Outflow related to exceptional items                              (105)   (287)
Net cash inflow from operating activities                        1,272     634
Returns on investments and servicing of finance                     58      53
Tax paid                                                           (86)    (60)
Capital expenditure and financial investment                      (345)   (295)
Acquisitions and disposals                                         (20)       -
Net cash inflow before management of liquid resources              879     332

and financing
Net (purchase)/issues of shares                                   (126)   (166)
Exchange and other movements                                       (42)     17
Increase in net cash funds in the period                           711     183
Net cash funds at beginning of period                            3,605   2,169
Net cash funds at end of period                                  4,316   2,352



Notes to the Interim Financial Statements

1 BASIS OF PREPARATION AND ACCOUNTING POLICIES


        The results for the quarter ended 31 March 2001 have been prepared in
        accordance with UK generally accepted accounting principles. The
        accounting policies applied are those set out in AstraZeneca PLC's
        2000 Annual Report and Form 20-F. In 2001, the continued
        standardisation of accounting treatments across AstraZeneca has led
        certain subsidiaries to classify as cost of sales some elements of
        expense recorded as distribution costs in previous periods. The effect
        of this change in the current period is to reclassify approximately
        $30m of costs. These interim financial statements do not constitute
        statutory accounts within the meaning of Section 240 of the Companies
        Act 1985. Statutory accounts for the year ended 31 December 2000 will
        be filed with the Registrar of Companies following the Company's
        Annual General Meeting. The auditor's report on those accounts was
        unqualified and did not contain any statement under Section 237 of the
        Companies Act 1985.

2 TERRITORIAL SALES ANALYSIS
                                                                 % Growth
                                          1st           1st

                                      Quarter       Quarter           Constant

                                         2001          2000 Actual    Currency

                                           $m            $m

     USA                               2,139         2,021      6           6
     Japan                               178           156     14          26
     France                              238           231      3          13
     Germany                             168           175     (4)          5
     Italy                               150           153     (2)          9
     Sweden                               67            87    (23)        (15)
     UK                                  172           184     (7)          -
     Rest of World                       879           885     (1)         10
Total                                  3,991         3,892      3           7



3 PRODUCT SALES ANALYSIS
                                                                  % Growth
                                             1st          1st

                                         Quarter      Quarter          Constant

                                            2001         2000  Actual  Currency

                                              $m           $m
Gastrointestinal:
     Losec                                1,495        1,588      (6)       (3)
     Nexium                                  81            -     n/m       n/m
     Others                                  12           11       9         9
Total Gastrointestinal                    1,588        1,599      (1)        2
Cardiovascular:
     Zestril                                294          276       7        11
     Seloken                                151          106      42        49
     Plendil                                106          115      (8)       (3)
     Tenormin                                98          119     (18)      (11)
     Atacand                                 83           56      48        59
     Imdur                                   21           23      (9)        -
     Others                                  82           99     (17)       (9)
Total Cardiovascular                        835          794       5        11



3 PRODUCT SALES ANALYSIS CONT.


                                                                   % Growth
                                                  1st       1st

                                              Quarter   Quarter        Constant

                                                 2001      2000 Actual Currency

                                                   $m        $m
Respiratory:
     Pulmicort                                   200       174     15       22
     Rhinocort                                    56        41     37       42
     Accolate                                     49        55    (11)      (9)
     Oxis                                         32        27     19       30
     Bricanyl                                     28        34    (18)      (9)
     Symbicort                                     3         -    n/m      n/m
     Others                                       13        14     (7)       7
Total Respiratory                                381       345     11       18
Oncology:
     Zoladex                                     160       167     (4)       3
     Nolvadex                                    139       139      -        3
     Casodex                                     115       115      -        5
     Arimidex                                     43        37     16       24
     Others                                        7         7      -        -
Total Oncology                                   464       465      -        5
CNS:
     Seroquel                                    189        82    130      132
     Zomig                                        66        65      2        5
     Other CNS                                     2         8    n/m      n/m
Total CNS                                        257       155     66       69
Pain, Infection and Other Pharma:
     Diprivan                                    107       164    (35)     (31)
     Merrem                                       49        36     36       44
     Xylocaine                                    47        54    (13)      (7)
     Marcaine                                     19        21    (10)      (5)
     Naropin                                      15        13     15       23
     Other Pharma Products                       127       142    (11)      (7)
Total Pain, Infection and Other Pharma           364       430    (15)     (10)
     Salick Health Care                           45        45      -        -
     Astra Tech                                   30        28      7       18
     Marlow Foods                                 27        25      8       20
     Other                                         -         6    n/m      n/m
                                                 102       104     (2)       4
Total                                          3,991     3,892      3        7



 n/m     not meaningful



Shareholder Information

ANNOUNCEMENTS AND MEETINGS

------------------------------------------------------------------------------
Annual General Meeting                                        26 April 2001
Announcement of half year results                             26 July 2001
Announcement of third quarter and nine month results          24 October 2001



DIVIDENDS

------------------------------------------------------------------------------

The record date for the second interim dividend payable on 9 April 2001 (in
the UK, Sweden and the US) was 23 February 2001. Ordinary Shares traded
ex-dividend on the London and Stockholm Stock Exchange from 21 February 2001.
ADSs traded ex-dividend on the New York Stock Exchange from the same date.

Future dividends will normally be paid as follows:
First interim       Announced end of July and paid in October.
Second interim      Announced in February and paid in April.





TRADEMARKS

------------------------------------------------------------------------------

All products or brand names included in Note 3 of this Interim Statement and
the following names are trademarks of, or licensed to, AstraZeneca PLC or its
subsidiary companies:

Atacand HCT Atacand Plus Crestor Faslodex Iressa Prilosec Pulmicort Respules
Rhinocort Aqua Toprol-XL Viozan Zomig Rapimelt Zomig ZMT



ADDRESSES FOR CORRESPONDENCE

------------------------------------------------------------------------------
Registrar and        Depositary        Registered       Swedish Securities
                                       Office
Transfer Office      for ADRs                           Register Centre
The AstraZeneca      Morgan Guaranty   15 Stanhope Gate Vardepapperscentralen
Registrar            Trust                              VPC AB
Lloyds TSB           Company of New    London           Box 7822
Registrars           York
The Causeway         ADR Service       W1K 1LN          S-103 97 Stockholm
                     Center
Worthing             PO Box 842006                      Sweden
West Sussex          Boston, MA
                     02284-2006
BN99 6DA
Tel: [phone] Tel: (781) 575    Tel: [phone]  Tel: [phone]
                     4328              5000



CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

------------------------------------------------------------------------------

In order to utilise the 'Safe Harbor' provisions of the United States Private
Securities Litigation Reform Act of 1995, AstraZeneca is providing the
following cautionary statement. This Interim Report contains forward-looking
statements with respect to the financial condition, results of operations and
businesses of AstraZeneca. By their nature, forward-looking statements and
forecasts involve risk and uncertainty because they relate to events and
depend on circumstances that will occur in the future. There are a number of
factors that could cause actual results and developments to differ materially
from that expressed or implied by these forward-looking statements. These
factors include, among other things, exchange rate fluctuations, the risk that
research and development will not yield new products that achieve commercial
success, the impact of competition, price controls and price reductions, the
risk of loss or expiration of patents or trade marks, difficulties of
obtaining and maintaining governmental approvals for products, the risk of
substantial product liability claims, exposure to environmental liability and
the risks related to the difficulty of completing the integration of Astra's
and Zeneca's large and complex businesses on a timely basis and realising
synergies.